<DOC>
	<DOCNO>NCT00479583</DOCNO>
	<brief_summary>The purpose research study determine high dose BMS-690514 safely give combination chemotherapeutic regimen ( FOLFIRI FOLFOX ) patient advance cancer</brief_summary>
	<brief_title>Combination Trial BMS-690514 Combination With FOLFIRI FOLFOX</brief_title>
	<detailed_description />
	<criteria>Patients eligible FOLFIRI FOLFOX therapy ECOG performance status score 01 At least 4 week since last chemotherapy , immunotherapy radiotherapy : At least 4 week since anticancer hormonal therapy OR target therapy ( instance tamoxifen Tarceva ) No maximum age Study Arm A ( FOLFOX ) 1865 year age Study Arm B ( FOLFIRI ) Treatment TKIs within past 4 week Active inflammatory bowel disease Major gastrointestinal surgery may affect absorption drug , surgery within last 4 week History thromboembolism Severe unmanageable diarrhea Uncontrolled significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Cancer ( solid tumor )</keyword>
</DOC>